Over the past 18 months, Permanent Intraocular Lens industry trends have been reshaped by a wave of strategic consolidation and rapid innovation. Johnson & Johnson Vision’s $3.2-billion buyout of TrueVision’s adaptive-technology platform (Q3-2023) fused AI-driven guidance with premium IOLs, accelerating demand for personalized refractive cataract packages while pressuring mid-tier manufacturers to differentiate. Alcon followed in Q1-2024 with the U.S. launch of Vivity Plus, a hydrophobic acrylic lens that extends depth-of-focus through wavefront-shaping nano-optics; the company simultaneously partnered with Veracity Innovations to bundle the lens with cloud-based biometric planning, pushing surgeons toward integrated workflow models. In Europe, Rayner’s October 2023 acquisition of German-based Chromophore Labs unlocked violet-light-filtering coatings, aligning with post-pandemic consumer preference for blue-blocking optics and digital-device comfort. Regulatory momentum also shifted: the FDA’s 2024 draft guidance lowered the barrier for extended-range-of-vision claims if real-world patient-reported outcomes are submitted, enticing start-ups to enter the segment. Investors responded—ReVision Optics closed a $48 million Series C in March 2024 to scale its adjustable hydrogel IOL, and both BVI Medical and PhysIOL expanded Malaysian and Brazilian manufacturing footprints to secure cost-effective supply chains outside China.
